1. Home
  2. ABEO vs BNY Comparison

ABEO vs BNY Comparison

Compare ABEO & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • BNY
  • Stock Information
  • Founded
  • ABEO 1974
  • BNY 2001
  • Country
  • ABEO United States
  • BNY United States
  • Employees
  • ABEO N/A
  • BNY N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • BNY Trusts Except Educational Religious and Charitable
  • Sector
  • ABEO Health Care
  • BNY Finance
  • Exchange
  • ABEO Nasdaq
  • BNY Nasdaq
  • Market Cap
  • ABEO 256.9M
  • BNY 232.5M
  • IPO Year
  • ABEO 1980
  • BNY N/A
  • Fundamental
  • Price
  • ABEO $5.57
  • BNY $9.74
  • Analyst Decision
  • ABEO Strong Buy
  • BNY
  • Analyst Count
  • ABEO 6
  • BNY 0
  • Target Price
  • ABEO $18.00
  • BNY N/A
  • AVG Volume (30 Days)
  • ABEO 1.1M
  • BNY 52.7K
  • Earning Date
  • ABEO 08-11-2025
  • BNY 01-01-0001
  • Dividend Yield
  • ABEO N/A
  • BNY 3.93%
  • EPS Growth
  • ABEO N/A
  • BNY N/A
  • EPS
  • ABEO N/A
  • BNY N/A
  • Revenue
  • ABEO N/A
  • BNY N/A
  • Revenue This Year
  • ABEO N/A
  • BNY N/A
  • Revenue Next Year
  • ABEO $323.51
  • BNY N/A
  • P/E Ratio
  • ABEO N/A
  • BNY N/A
  • Revenue Growth
  • ABEO N/A
  • BNY N/A
  • 52 Week Low
  • ABEO $3.93
  • BNY $8.60
  • 52 Week High
  • ABEO $7.32
  • BNY $10.80
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 37.51
  • BNY 56.39
  • Support Level
  • ABEO $5.66
  • BNY $9.59
  • Resistance Level
  • ABEO $6.24
  • BNY $9.69
  • Average True Range (ATR)
  • ABEO 0.26
  • BNY 0.08
  • MACD
  • ABEO -0.08
  • BNY 0.02
  • Stochastic Oscillator
  • ABEO 8.08
  • BNY 94.74

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

About BNY BlackRock New York Municipal Income Trust

Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.

Share on Social Networks: